.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 4,559,332

« Back to Dashboard

Claims for Patent: 4,559,332

Title: 20-Spiroxanes and analogues having an open ring E, processes for their manufacture, and pharmaceutical preparations thereof
Abstract:Steroid compounds of the 20-spiroxane series and their analogues having an open ring E of the formula, ##STR1## in which --A--A-- represents the group --CH.sub.2 --CH.sub.2 -- or --CH.dbd.CH--, R.sup.1 represents hydrogen, and R.sup.2 represents an .alpha.-oriented lower alkoxycarbonyl radical, or R.sup.1 and R.sup.2 together represent an .alpha.- or a .beta.-oriented methylene radical, --B--B-- represents the group --CH.sub.2 --CH.sub.2 -- or an .alpha.- or .beta.-oriented group ##STR2## X represents two hydrogen atoms or oxo, Y.sup.1 and Y.sup.2 together represent the oxygen bridge --O--, or Y.sup.1 represents hydroxy, and Y.sup.2 represents hydroxy, lower alkoxy or, if X represents H.sub.2, also lower alkanoyloxy, and salts of compounds in which X represents oxo and Y.sup.2 represents hydroxy, are distinguished as effective aldosterone-antagonists with minimal side-effects and, for that reason, are especially suitable for the treatment of all forms of hyperaldosteronism.
Inventor(s): Grob; Jurgen (Giebenach, CH), Kalvoda; Jaroslav (Binningen, CH)
Assignee: Ciba Geigy Corporation (Ardsley, NY)
Application Number:06/598,109
Patent Claims: 1. A steroid compound of the formula ##STR13## in which --A--A-- represents the group --CH.sub.2 --CH.sub.2 -- or --CH.dbd.CH--,

R.sup.1 represents hydrogen, and

R.sup.2 represents an .alpha.-oriented lower alkoxycarbonyl radical, or

R.sup.1 and R.sup.2 together represent an .alpha.- or a .beta.-oriented methylene radical,

--B--B-- represents the group --CH.sub.2 --CH.sub.2 -- or an .alpha.- or .beta.-oriented group ##STR14## X represents two hydrogen atoms or oxo, Y.sup.1 and Y.sup.2 together represent the oxygen bridge --O--, or

Y.sup.1 represents hydroxy, and

Y.sup.2 represents hydroxy, lower alkoxy or, if X represents H.sub.2, also lower alkanoyloxy,

and salts of compounds in which X represents oxo and Y.sup.2 represents hydroxy.

2. A compound according to claim 1, in which R.sup.2 represents methoxycarbonyl, ethoxycarbonyl or isopropoxycarbonyl.

3. A compound according to claim 1, in which R.sup.1 and R.sup.2 together represent a .beta.-oriented methylene radical.

4. A compound according to claim 1, in which --B--B-- represents the .beta.-oriented group ##STR15##

5. A compound according to claim 1, in which X represents oxo.

6. A compound according to claim 1, in which Y.sup.1 and Y.sup.2 together represent the oxygen bridge --O--.

7. A compound according to claim 1, in which R.sup.1 and R.sup.2 together represent a methylene group, X represents oxo and each of Y.sup.1 and Y.sup.2 represents hydroxy.

8. An alkali metal salt of a compound according to claim 7.

9. A potassium salt of a compound according to claim 7.

10. A compound according to claim 1, which is 9.alpha.,11.alpha.-epoxy-7.alpha.-methoxycarbonyl-20-spirox-4-ene-3,21-dio ne.

11. A compound according to claim 1, which is 9.alpha.,11.alpha.-epoxy-7.alpha.-isopropoxycarbonyl-20-spirox-4-ene-3,21- dione.

12. A compound according to claim 1, which is 9.alpha.,11.alpha.-epoxy-6.alpha.,7.alpha.-methylene-20-spirox-4-ene-3,21- dione.

13. A compound according to claim 1, which is 9.alpha.,11.alpha.-epoxy-6.beta.,7.beta.-methylene-20-spirox-4-ene-3,21-di one.

14. A pharmaceutical composition containing as active ingredient one of the compounds defined in claim 1.

15. A pharmaceutical composition containing an effective amount of an aldosterone-antagonistic compound according to claim 1, and at least one diuretic which is non-specific with regard to electrolytes and which increases diuresis by renal and by extrarenal action on tissue.

16. A therepeautic method for controlling hyperaldosteronism in humans and other warm-blooded animals, comprising the administration of an effective amount of a compound according to claim 1, in the presence or absence of a pharmaceutically acceptable carrier.

17. A therapeutic method for controlling hyperaldosteronism in humans and other warm blooded animals, comprising the simultaneous administration of an effective amount of a compound according to claim 1, together with at least one diuretic which is non-specific with regard to electrolytes and which increases diuresis by renal and by extrarenal action on tissue.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc